跳至主要内容
临床试验/ISRCTN17632637
ISRCTN17632637已完成不适用

Effects of olanzapine standard oral tablets and orally disintegrating tablets on gut hormones, glucose metabolism and pituitary hormones

eiden University Medical Centre (LUMC) (The Netherlands)0 个研究点目标入组 12 人开始时间: 2007年4月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Healthy men without a positive family history of schizophrenia
  • 2. Age between 20 and 40 years
  • 3. Fasting plasma glucose less than 6 mmol/L
  • 4. Body Mass Index (BMI) between 20 and 26 kg/m^2

排除标准

  • 1. Fasting plasma glucose greater than 6 mmol/L
  • 2. BMI greater than 26 kg/m^2
  • 3. Psychiatric disorder and/or use of antipsychotic or antidepressants drugs at present or in the past
  • 4. Gastrointestinal operations in the past
  • 5. Any significant chronic disease
  • 6. Renal, hepatic or endocrine disease
  • 7. Use of medication known to influence lipolysis and or glucose metabolism
  • 8. Total cholesterol greater than 7 mmol/L and or triglycerides greater than 2 mmol/L
  • 9. Recent weight changes or attempts to lose weight (greater than 3 kg weight gain or loss, within the last three months)
  • 10. Difficulties to insert an intravenous catheter
  • 11. Smoking (current)
  • 12. Alcohol/drug abuse
  • 13. Severe claustrophobia
  • 14. Recent blood donation (within the last two months)
  • 15. Recent participation in other research projects (within the last three months), participation in two or more projects in one year
  • 16. Extensive sporting activities (more than ten hours of exercise per week)

研究者

发起方
eiden University Medical Centre (LUMC) (The Netherlands)

相似试验

Effects of olanzapine standard oral tablets and... | 临床试验